Hallo biotechfreaks,hier einechter Knaller,leider nur am OTC bulletin board handelbar:
On the subject of Dendreon and Provenge, it's tough to leave Immunocellular Therapeutics (IMUC.ob) out of the conversation, as this company may be following in Dendreon's footsteps to become the leader of the next generation of cancer immunotherapy treatment.
Because Immunocellular views its technology as the next step in the realm of cancer immunotherapies, one should also consider the company as a perpetual candidate to either be bought out or land a major partnership.
IMUC's technology, from which lead candidate ICT-107 was devised for the treatment of glioblastoma (GBM), attacks the stem cells behind the growth and spreading of cancer. Maybe even more important than the step forward in the technology, however, may be the logistical advantages that the company has developed in production and manufacturing, which significantly reduces the costs associated with production.
Given that much of Dendreon's recent troubles stem from the high cost of Provenge treatment, IMUC's logistical advantage should be noted. Patients treated with ICT-107, for example, need to have their dendritic cells harvested only once, while those receiving Provenge need this process conducted three times during treatment, elevating the cost of treatment.
ICT-107 is still a Phase II product, but the development of this treatment and the technology should be monitored by investors of the sector, with DNDN being the example of what comes with a successful cancer immunotherapy stock.
MFG
Chali
On the subject of Dendreon and Provenge, it's tough to leave Immunocellular Therapeutics (IMUC.ob) out of the conversation, as this company may be following in Dendreon's footsteps to become the leader of the next generation of cancer immunotherapy treatment.
Because Immunocellular views its technology as the next step in the realm of cancer immunotherapies, one should also consider the company as a perpetual candidate to either be bought out or land a major partnership.
IMUC's technology, from which lead candidate ICT-107 was devised for the treatment of glioblastoma (GBM), attacks the stem cells behind the growth and spreading of cancer. Maybe even more important than the step forward in the technology, however, may be the logistical advantages that the company has developed in production and manufacturing, which significantly reduces the costs associated with production.
Given that much of Dendreon's recent troubles stem from the high cost of Provenge treatment, IMUC's logistical advantage should be noted. Patients treated with ICT-107, for example, need to have their dendritic cells harvested only once, while those receiving Provenge need this process conducted three times during treatment, elevating the cost of treatment.
ICT-107 is still a Phase II product, but the development of this treatment and the technology should be monitored by investors of the sector, with DNDN being the example of what comes with a successful cancer immunotherapy stock.
MFG
Chali
